Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

April 7, 2025

FDA grants breakthrough therapy status for Amgen’s Uplizna to treat IgG4-RD

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Amgen’s humanised monoclonal antibody Uplizna (inebilizumab-cdon) to treat the adult population with immunoglobulin G4-related disease (IgG4-RD), an immune-mediated inflammatory condition that impacts several organs.

FDA grants breakthrough therapy status for Amgen’s Uplizna to treat IgG4-RD